Monimala Saha1, Aparna Chakraborty2, Sandip Chattopadhyay1, Subhendu Saha3, Joydip Paul1, Anjan Das4
1Department of Gynecology and Obstetrics, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India.
2Department of Gynecology and Obstetrics, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
3Department of Pediatric Medicine, Malda Medical College, Malda, West Bengal, India.
4Department of Anaesthesiology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India.
DOI: 10.4103/0976-9668.166116
ABSTRACT
Background: Misoprostol is very effective in cervical ripening and is used for termination of pregnancy. A similar effect on the nonpregnant uterus will facilitate gynecological operations, and hence we assessed the effect of misoprostol on the nonpregnant uterus of premenopausal women. Materials and Methods: In a prospective double-blinded randomized controlled trial, 280 women were randomly allocated into two groups (12 women did not complete the intervention). Study (A) and control (B) group received 400 μg of misoprostol or 400 mg of metronidazole tablets (as a placebo) respectively in the posterior vaginal wall 6 h prior to gynecological procedures. Results: The mean cervical dilatation was significantly higher (P < 0.0001) in misoprostol compared to placebo group (4.6 ± 0.96 mm vs. 3.6 ± 0.82 mm), benefit were also observed on secondary outcome measures which were need for further dilatation, time taken for further dilatation, ease of dilatation, subjective assessment of pain by visual analog scale. Only 3.61% patients complained of intolerable pain during dilatation in the study group while in control group 48.74% complained of intolerable pain and required anesthesia. Most common side effects of misoprostol were abdominal pain and mild vaginal bleeding. Conclusion: Misoprostol was effective in cervical ripening of nonpregnant premenopausal uterus to facilitate gynecological procedures.
Keywords: Cervical dilatation, misoprostol, nonpregnant.
